Evaluating Myocardial Viability in Ischemic Heart Disease Using Integrated 18F-FDG PETMR Imaging Before Surgery

What this Trial Is About

Researchers are evaluating the accuracy of myocardial imaging using integrated 18F-FDG PETMR to detect viable heart muscle in patients with ischemic heart disease. The study also aims to see if this imaging method can replace the current standard that combines 18F-FDG PET with 99mTc MIBI SPECTCT gated myocardial perfusion imaging. This is important as assessing heart muscle viability helps predict treatment success and select the best surgical options, especially before coronary artery bypass grafting CABG. Participants will undergo two procedures within two weeks before surgery an integrated 18F-FDG PETMR scan, and a combined 18F-FDG PETMR plus 99mTc MIBI gated myocardial perfusion imaging. These imaging techniques allow doctors to evaluate heart blood flow, metabolism, muscle vitality, and function simultaneously. The study focuses on patients with significant coronary artery narrowing and reduced heart function, some of whom may also receive stem cell treatments alongside CABG. During the study, participants will sign informed consent and complete the imaging scans, with outcome measures including myocardial perfusion and metabolic imaging assessed approximately two days after the scans. Researchers will monitor heart function and muscle viability to help determine surgical outcomes. The study runs until 2026 and involves adults under 80 years with specific heart conditions, ensuring comprehensive assessments to support future heart disease treatments.

A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR